Mayne Pharma Group Limited

Mayne Pharma Group Limited

MAYNF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$311.17M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Mayne Pharma Group LimitedMayne Pharma Group Limited10.6--18%0.40.1

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$311.17 Million
Enterprise Value$272.12 Million
Earnings per Share$0.3
Beta1
Outstanding Shares81,245,827

Return

Return on Equity-17.74%ROE
Return on Assets-7.63%
Return on Invested Capital-11.94%

Valuation & Multiples

P/E Ratio10.65P/E Ratio
PEG-6.75PEG
Price to Sales0.43Price to Sales
Price to Book Ratio0.96Price to Book Ratio
Enterprise Value to Revenue0.34
Enterprise Value to EBIT-3.51
Enterprise Value to Net Income-4
Total Debt to Enterprise0.16
Debt to Equity0.11Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 26, 2026
EPS
-$0.25
Est. -$0.24
Revenue
$118.81 M
Est. $115.39 M

Next Earnings Call

Expected Date
February 24, 2027
EPS Estimate
-$0.14
Consensus analyst estimate
Revenue Estimate
$136.13 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Mayne Pharma Group Limited

450 employees
CEO: Aaron Gray

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Aus...

Questions & Answers